- Global Pharma News & Resources

Global Nasal Polyps Treatment Market 2020 Growth Trends by Manufacturers, Regions, Type and Application, Forecast 2027|OptiNose US, Inc., Lyra Therapeutics, Intersect ENT, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Sanofi

Pune, Maharashtra, India, July 1 2020 (Wiredrelease) Data Bridge Market Research — Global nasal polyps treatment market is rising gradually with a substantial CAGR 5.3% in the forecast period of 2020-2027. This report contains the data of base year 2019 and historic year of 2018.  Screening methods, increasing geriatric population and development pf newer minimal invasive therapies are expected to propel the market growth.

This nasal polyps treatment report also includes geographical markets and key players that have adopted significant strategies for business developments. The data and information regarding the healthcare industry are taken from trustworthy sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the market experts. This market report assesses the production processes, major issues, and solutions to mitigate the development risk. The nasal polyps treatment report encompasses the key developments in the market with respect to current scenario and the forthcoming advancements. This is the quality market report which has transparent market research studies and estimations that supports business growth.

Ask For Complimentary Sample PDF| Request At

Few of the major competitors currently working in the global nasal polyps treatment market are Regeneron Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc., OptiNose US, Inc., Lyra Therapeutics, Intersect ENT, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd, Blacksmith Surgical, Pfizer Inc., Bausch Health, Alkermes, AstraZeneca, Mallinckrodt, Dr. Reddy’s Laboratories Ltd, Lonza, among others.

Key Developments in the Market:

In June 2019, Novartis AG announced the positive topline results of phase III clinical trial studies of Xolair (omalizumab), an immunoglobulin E (IgE) blocker used for the treatment of patients with chronic rhinosinusitis with nasal polyps. The purpose of this study is for evaluation of safety and efficacy profile of the drug. Xolair is a potent drug that can replace intranasal corticosteroids and nasal polyp surgery

In June 2019, Regeneron Pharmaceuticals, Inc. received the U. S. FDA approval for Dupixent (dupilumab), the first drug that is used for the treatment of patients with chronic rhinosinusitis with nasal polyps. This drug is potentially beneficial for patients that do not respond to intranasal steroids used in nasal popyps condition. Additionally, use of dupixent will reduce the requirement of nasal polyp surgery

Table Of Content:

Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Global Nasal Polyps Treatment Market Landscape

Part 04: Global Nasal Polyps Treatment Market Sizing

Part 05: Global Nasal Polyps Treatment Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape
Part 08: Geographic Landscape

Part 09: Decision Framework
Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Get Full Table Of content @

Segmentation: Global Nasal Polyps Treatment Market

By Type

(Ethmoidal Polyp, Antrochoanal Polyp and Others),

Related Diseases

(Chronic Sinusitis, Cystic Fibrosis (CF), Allergic Fungal Sinusitis (AFS) and Others),


(Obstructive Sleep Apnea, Sinus Infections and Others),


(Nasal Endoscopy, Blood Test, Allergy Tests and Others),


(Medication, Surgery and Others),


(Nasal Corticosteroids, Medication to Treat Nasal Polyps and Chronic Sinusitis and Others),

Route of Administration

(Oral, Injectable and Others),

End Users

(Hospitals, Homecare, Specialty Clinics, Others),

Distribution Channel

(Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others),


(North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Market Drivers

Increasing geriatric population that are more vulnerable for development of nasal polyps is expected to drive the market growth

Growing screening for diagnosis of asymptomatic diseases like nasal polyps, boosting the market growth

Rising awareness about the disease and its complications drive the growth of market

Development of minimally-invasive surgical treatments and therapies will fuel up the global nasal polyps treatment market

Market Restraints

Factors that hinders the market growth are bleeding and infection during surgery

Low healthcare expenditure in some countries hampers the market growth

High cost treatment options and post-surgical complications are major restrains for the market growth

Inquiry For Customize Report With Discount at :

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research
Tel: +1-888-387-2818


This content has been published by Data Bridge Market Research company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 01-Jul-2020